Skip to main content
. 2023 Jun 15;15:127. doi: 10.1186/s13098-023-01057-2

Table 2.

Results of subgroup analyses based on various independent variables

Outcomes stratified by different covariates No.
studies
Pooled effect size (95% CI) P-value I2 (%) P-heterogeneity

FPG, Overall (WMD)

Gender

Women

Both

Sample size

> 500

≤ 500

Population

PCOS

T2DM

Other

6

2

4

4

2

2

3

1

-10.9 (-16.2, -5.65)

-5.24 (-8.7, -1.81)

-15.6 (-21.6, -9.56)

-13.0 (-20.1, -5.88)

-5.65 (-10.7, -0.58)

-5.24 (-8.66, -1.81)

-20.3 (-27.8, -12.8)

-11.4 (-16.31, -6.47)

< 0.001

0.003

0.000

< 0.001

0.029

0.003

< 0.001

< 0.001

66

0.0

28.4

75.1

0.0

0.0

0.0

-

0.01

0.97

0.24

0.01

0.45

0.97

0.83

-

FPG, Overall (SMD)

Sample size

> 500

≤ 500

Population

PCOS

T2DM

5

2

3

1

4

-0.86 (-1.19, -0.52)

-0.59 (-0.92, -0.25)

-1.15 (-1.84, -0.46)

-0.87 (-1.68, -0.07)

-0.88 (-1.28, -0.48)

< 0.001

< 0.001

< 0.001

0.034

< 0.001

53,1

0.0

66.6

-

64.7

0.07

0.54

0.05

-

0.04

HbA1C, Overall (WMD)

Sample size

≥ 1000

< 1000

Population

T2DM

Other

8

3

5

6

2

-0.10 (-0.17, -0.03)

-0.16 (-0.25, -0.06)

-0.06 (-0.15, 0.03)

-0.09 (-0.14, -0.05)

0.01 (-0.51, 0.53)

0.003

< 0.001

0.219

< 0.001

0.962

28.2

0.0

31.9

0.0

85.1

0.20

0.41

0.21

0.71

0.01

Abbreviations: FPG; Fasting plasma glucose, PCOS; Polycystic ovary syndrome, T2DM; Type 2 diabetes mellitus, HbA1C; Hemoglobin A1C, WMD; Weighted mean difference, SMD; Standardized mean difference, MD; Mean difference, CI; Confidence interval; Other: study populations other than T2DM and PCOS